Inhibition of Interleukin 10 Enhances Antitumor Immune Activity in Liver Metastases of Human Colorectal Cancer
-
August 1, 2026
Objective:
To investigate the effects of interleukin 10 blockade on antitumor immune function in liver metastases of human colorectal cancer.
Approach:
- Study Design: The study involved experimental conditions comparing CAR-T therapy with and without IL-10 blockade.
Key Findings:
- Errors were identified in figure 5 and the Results section, specifically regarding the images used and the reported sample sizes for certain experimental conditions.
- The sample size for control CAR-T and anti-IL-10 antibody was corrected from n=4 to n=2, affecting the interpretation of the results.
- Statistical significance and p-values remained unchanged despite the corrections.
Interpretation:
The overall findings of the study remain consistent despite the corrections made to the data.
Limitations:
- The initial errors in figure 5 and the Results section may affect the interpretation of the data, particularly in understanding the efficacy of the treatments.
- Sample sizes were smaller than initially reported for some experimental conditions, which could limit the robustness of the findings.
Conclusion:
The authors confirmed that the corrections do not alter the overall findings of the study.
Sources:
Based on findings from:
Correction: Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases
Gut, 2026.
https://gut.bmj.com/content/75/8/e8
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.